Access

Article

Nature Medicine 10, 816 - 820 (2004)
Published online: 4 July 2004 | doi:10.1038/nm1076

RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia

Haibin Xia1,2,8, Qinwen Mao1,2,8, Steven L Eliason1,2, Scott Q Harper1,2, Inês H Martins1,2, Harry T Orr3,4, Henry L Paulson5, Linda Yang6, Robert M Kotin6 & Beverly L Davidson1,2,5,7

The dominant polyglutamine expansion diseases, which include spinocerebellar ataxia type 1 (SCA1) and Huntington disease, are progressive, untreatable, neurodegenerative disorders. In inducible mouse models of SCA1 and Huntington disease, repression of mutant allele expression improves disease phenotypes. Thus, therapies designed to inhibit expression of the mutant gene would be beneficial. Here we evaluate the ability of RNA interference (RNAi) to inhibit polyglutamine-induced neurodegeneration caused by mutant ataxin-1 in a mouse model of SCA1. Upon intracerebellar injection, recombinant adeno-associated virus (AAV) vectors expressing short hairpin RNAs profoundly improved motor coordination, restored cerebellar morphology and resolved characteristic ataxin-1 inclusions in Purkinje cells of SCA1 mice. Our data demonstrate in vivo the potential use of RNAi as therapy for dominant neurodegenerative disease.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

RNAi quashes polyQ

Nature Medicine News and Views (01 Aug 2004)

Research Highlights

Nature Biotechnology News and Views (01 Aug 2004)

See all 11 matches for News And Views

RESEARCH

Artificial MicroRNAs as siRNA Shuttles: Improved Safety as Compared to shRNAs In vitro and In vivo

Molecular Therapy Original Article

Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human

Nature Genetics Article (01 Sep 2000)

See all 41 matches for Research
$rb.Type.Code